Navigation Links
Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
Date:11/5/2012

By E.J. Mundell
HealthDay Reporter

MONDAY, Nov. 5 (HealthDay News) -- About a quarter of people who experience the dangerous blood clots in the legs or lungs known as venous thromboembolisms (VTEs) develop them for no discernable reason, and most will receive a powerful anti-clotting drug such as warfarin in the months after the clot forms.

But what about longer-term care, to ward off a recurrent clot, or events such as heart attack or stroke? A new study suggests that patients who go on low-dose daily aspirin after they are weaned off more powerful anticoagulants can derive real benefit.

While this study alone could not show a significant effect for aspirin therapy in preventing a recurrent clot for these patients, it did show a significant lowering of overall cardiovascular risk for such complications as heart attack, stroke, major bleeding or death from any cause.

The study was presented Sunday at the American Heart Association's annual meeting in Los Angeles, and was published simultaneously in the New England Journal of Medicine.

The study authors said they saw a "non-significant" trend hinting at aspirin's ability to prevent a second VTE, but the study group was simply too small to push that to statistical significance.

However, they added, when the findings from this study were combined with those of a similar trial called WARFASA, the combined data did show that daily aspirin could prevent recurrent blood clots.

"The essential message of the study that we are presenting today, and combining that with the WARFASA study that was published earlier this year in the NEJM, is that aspirin does have a benefit: about a 30 percent risk reduction of recurrent vein thrombosis, and also about a similar effect in reducing other major vascular events stroke, myocardial infarction [heart attack] and cardiovascular death," said study author Timothy Brighton, a consultant hematologist in Sydney, Australia.

VTEs include sudden, potentially life-threatening clots in the legs (known as deep vein thrombosis, or DVT) and clots that travel to the lungs, called pulmonary embolisms.

As Brighton explained, in about 75 percent of cases, these clots have a known cause injury, surgery or underlying illness, for example. But for the other quarter of patients, the cause is unknown.

More than 800 people with a VTE of uncertain cause were included in the new study. Approximately half were given low-dose (100 milligrams/day) daily aspirin, while the other half received a placebo, after they had completed their initial regimen of a more powerful anticoagulant. The patients were then followed for an average of more than three years.

Brighton noted that patients often cannot continue on anticoagulants such as warfarin indefinitely, because of bleeding risks and inconveniences associated with these drugs.

"The question comes, though, after [discontinuation of initial anti-coagulation therapy], what do you do?" he said.

The answer, from the new study as well as WARFASA, seems to be low-dose daily aspirin. Brighton's group also pointed out that incidents of bleeding were similar for those on low-dose aspirin and placebo, suggesting that aspirin does not raise bleeding risk.

One cardiologist said the study is encouraging for patients. Dr. Stephen Green, associate chairman of the department of cardiology at North Shore University Hospital in Manhasset, N.Y., said that while it's true the trial (on its own) did not find a significant effect of aspirin in reducing VTE recurrence, "the study was positive enough that physicians should consider adding aspirin when stopping warfarin in patients who are reasonable candidates for long-term aspirin."

But he also noted that since the time of the trial, many patients with VTE have now moved from initial warfarin therapy to treatment with newer blood-thinning agents such as Xarelto and Pradaxa.

More study might be needed to assess aspirin's effectiveness in that clinical scenario, he said.

More information

Find out more about deep vein thrombosis at the U.S. National Library of Medicine.

SOURCES: Timothy Brighton, MB, BS, consultant hematologist, Sydney, Australia; Stephen Green, M.D., associate chairman, department of cardiology, North Shore University Hospital, Manhasset, N.Y.; Nov 4, 2012, presentation, American Heart Association annual meeting, Los Angeles; Nov. 4, 2012, New England Journal of Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Daily Aspirin May Bolster Aging Brain, Study Shows
2. BMJ and Daily Telegraphs fake hip exposes failing European device regulation
3. Daily disinfection of isolation rooms reduces contamination of healthcare workers hands
4. For Mild Asthma, Daily Steroids May Not Be Needed, Study Says
5. AAO-HNSF 2012 daily miniseminars highlights
6. AAO-HNSF 2012 new oral research daily highlights
7. Daily Temper Tantrums Not the Norm for Preschoolers: Study
8. Daily Aspirin May Help Fight Prostate Cancer, But Not Breast Cancer
9. Working moms spend less time daily on kids diet, exercise, study finds
10. Daily Aspirin May Cut Cancer Deaths, Another Study Finds
11. Daily aspirin usage associated with lower cancer mortality
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... DrugDev ... study is whether they can trust the sponsor to pay them correctly and on ... sponsors and CROs establish payment strategies that encourage sites to work on their studies. ...
(Date:6/27/2017)... ... 2017 , ... The Congressional Budget Office (CBO) projects that the Better Care ... Protection and Affordable Care Act (ACA), would result in 22 million Americans losing their ... , More than 20 million Americans have gained health insurance under the ACA, and ...
(Date:6/27/2017)... ... , ... A January 18th article on medGadget reports that the ... the year 2024 according to a new report. The article also notes that the ... Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that it ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... HORSHAM, Pa. , June 19, 2017  Researchers ... announced today that they will host a live, complimentary ... Perspectives from the benchtop to the real world" on ... PM EDT. This webinar will feature ... a rare look into the manipulation techniques abusers use ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: